Will Ozempic / semaglutide be FDA-approved for Alzheimer's before 2030?
15
124
Ṁ710Ṁ270
2030
68%
chance
1D
1W
1M
ALL
Semaglutide (brand names: Ozempic, Rybelsus, and Wegovy) is an antidiabetic and anti-obesity drug. Its developer, Novo Nordisk, has three ongoing phase 3 trials run across the world of semaglutide for Alzheimer’s disease:
NCT04777396: 1,840 participants, started in 2021, results expected in 2026,
NCT05891496: 24 participants, started in 2023, results expected in 2025,
NCT04777409: 1,840 participants, started in 2021, results expected in 2026.
Will semaglutide be approved by the Food and Drug Administration (FDA) for Alzheimer's (or any kind of cognitive impairment) before January 1st, 2030?
Approval can be for the treatment (whether symptomatic or disease-modifying) or prevention of the targeted disease.
Get Ṁ200 play money
Related questions
Will a senolytic drug be used clinically to slow, prevent, or reverse aging by the end of 2033?
49% chance
Will AOH1996 be FDA approved before 2040?
45% chance
The FDA will warn about overuse or misuse of semaglutide (Ozempic, Wegovy and Rybelsus) before the end of 2024.
33% chance
Will Pfizer announce a weight loss drug competing with Ozempic and Wygovy before 12/31/2024?
39% chance
Will there be a recall of Wegovy/Ozempic before 2035?
45% chance
Will a vaccine for HIV be approved by the FDA by 2030?
66% chance
Will Ozempic be ranked within the top three prescribed drugs for diabetes by June 30, 2024?
3% chance
Will 10 million Americans be on semaglutide (or yet-to-be-approved equally good or superior alternatives) by the end of 2030?
73% chance
Will Matt Kaeberlein start taking semaglutide/ozempic by 2030?
41% chance
Will Alzheimer’s be cured by 2040?
60% chance